A first step towards preventive medicine in multiple sclerosis

The results of the first randomized, placebo-controlled trial of dimethyl fumarate in a cohort of participants with radiologically isolated syndrome showed efficacy against the risk of a first clinical demyelinating event. The findings pave the way for preventive medicine in multiple sclerosis and highlight the need for more precise prognostication of risk.

Automated summary

The first randomized, placebo-controlled trial of dimethyl fumarate in radiologically isolated syndrome patients demonstrated its efficacy in reducing the risk of a first clinical demyelinating event. These findings provide a foundation for preventive medicine in multiple sclerosis and underscore the importance of precise risk prognostication.